Synthaverse S.A. (FRA:6NQ)

Germany · Delayed Price · Currency is EUR

0.874

-0.007 (-0.79%)

At close: Dec 4, 2025

5.17% (1Y)

Market Cap	62.73M
Revenue (ttm)	16.77M
Net Income (ttm)	1.76M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	35.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.881
Previous Close	0.881
Day's Range	0.873 - 0.881
52-Week Range	0.798 - 1.378
Beta	n/a
RSI	33.77
Earnings Date	Nov 19, 2025

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1944

Employees 239

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6NQ

Full Company Profile

Financial Performance

In 2024, Synthaverse's revenue was 71.76 million, an increase of 22.44% compared to the previous year's 58.61 million. Earnings were 7.55 million, an increase of 58.68%.

Financial numbers in PLN Financial Statements

News

There is no news available yet.